Printer Friendly

AMERICAN CYANAMID ANNOUNCES NEW USE FOR ANASTOMOSIS TECHNOLOGY TO AID PHYSICIANS AND PATIENTS

 AMERICAN CYANAMID ANNOUNCES NEW USE FOR ANASTOMOSIS TECHNOLOGY
 TO AID PHYSICIANS AND PATIENTS
 WAYNE, N.J., Dec. 17 /PRNewswire/ -- American Cyanamid Company (NYSE: ACY) today announced the following:
 Valtrac(A), a new and innovative biofragmentable anastomosis ring, is now available for expanded use to include multiple insertions in a single patient. Since it's introduction in April 1991, this device has been used for small and large bowel anastomosis -- the surgical joining of bowel segments to maintain or restore function.
 "The clinical benefits of Valtrac will be magnified by the new use, or when patients need more than one anastomosis. An important and unique feature of the device is that it fragments and passes out of the body, leaving nothing permanent at the anastomosis. Because nothing is left behind, the anastomosis is freer to expand or contract as needed," says Clayton Shatney, M.D., clinical professor of surgery at Stanford University School of Medicine in Stanford, Calif.
 People requiring trauma-related surgery as a result of automobile accidents or gunshot wounds, for example, are likely candidates for multiple insertions. Valtrac has also been successfully used in any disease process for which resection, or the removal of a portion of the bowel, and anastomosis is indicated. Examples include carcinoma, diverticular disease and Crohn's disease, as well as other conditions.
 According to Shatney, who participated in a worldwide multicenter trial of Valtrac, this new device has many other advantages. "One of the most important advantages of Valtrac is that this technique leaves nothing foreign in the body, such as with staples. It also provides for minimal tissue manipulation and trauma. Compared to sutures, it reduces procedure time, and Valtrac is stronger than suture or staple anastomosis. In addition, compared to staples, use of Valtrac provides the benefit of cost savings, which will be the major health care issue of the next decade."
 The device, manufactured by Davis & Geck, a division of American Cyanamid Company, is composed of a polyglycolic acid and provides a mechanical locking connection between two ends of the bowel, whether the anastomosis is end to end, end to side, or side to side. In addition to the many benefits of this new device, the incidence of adverse events is minimal and not significantly different than that seen in the other methods.
 Davis & Geck is one of the world's largest producers of surgical products with 75 years of industry experience. Its products are manufactured in eight countries, and sold in more than 60 nations.
 (A) -- Trademark American Cyanamid Company.
 -0- 12/17/91
 /CONTACT: Pam DeMala of American Cyanamid, Davis & Geck division, 201-831-2260/
 (ACY) CO: American Cyanamid Company; Davis & Geck ST: New Jersey IN: MTC SU:


TS-OS -- NY038 -- 2936 12/17/91 12:01 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 17, 1991
Words:453
Previous Article:ALASKA AIRLINES WINS APPROVAL FOR ROUTE BETWEEN SEATTLE, MEXICAN RESORTS; SERVICE TO START JAN. 31
Next Article:PHILADELPHIA ELECTRIC COMPANY REACHES OUT TO RECENTLY ARRIVED RUSSIAN-JEWISH IMMIGRANTS
Topics:


Related Articles
VITAL HEART SYSTEMS INTRODUCES A NEW TOOL FOR EMERGENCY DEPARTMENTS
AMERICAN CYANAMID AND PROGENICS PHARMACEUTICALS SIGN RESEARCH AGREEMENT
USS Introduces Worldus First Product Line For Minimally Invasive Coronary Artery Bypass;
/C O R R E C T I O N -- United States Surgical/(Correction Notice)
U.S. Surgical's One-Shot* Instrument For Minimally Invasive Heart Surgery Cleared by FDA
St. Jude Medical Completes Acquisition of Vascular Science, Inc., a Developer of New Devices to Treat Coronary Artery Disease.
FDA APPROVES ONUX MEDICAL EDOSCOPIC SUTURING SYSTEM.
R2 Technology Launches Pulmonary Artery Patency Exam Tool for CT.
Synovis Life Technologies' Microvascular Anastomotic Coupler System Found Effective in Connecting Arteries in Head and Neck Reconstruction.
Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host 'Innovations in Revascularization' Symposium.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters